BRPI0515596A - composição farmacêutica usada para o tratamento e/ou prevenção de hcv, e, métodos de inibir rna polimerase ns5b de hepatite c de tratar ou prevenir infecção por hepatite c em um mamìfero - Google Patents
composição farmacêutica usada para o tratamento e/ou prevenção de hcv, e, métodos de inibir rna polimerase ns5b de hepatite c de tratar ou prevenir infecção por hepatite c em um mamìferoInfo
- Publication number
- BRPI0515596A BRPI0515596A BRPI0515596-7A BRPI0515596A BRPI0515596A BR PI0515596 A BRPI0515596 A BR PI0515596A BR PI0515596 A BRPI0515596 A BR PI0515596A BR PI0515596 A BRPI0515596 A BR PI0515596A
- Authority
- BR
- Brazil
- Prior art keywords
- hepatitis
- mammal
- treating
- infection
- hcv
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
"COMPOSIçãO FARMACêUTICA USADA PARA O TRATAMENTO E/OU PREVENçãO DE HCV, E, MéTODOS DE INIBIR RNA POLIMERASE NS5B DE HEPATITE C E DE TRATAR OU PREVENIR INFECçãO POR HEPATITE C EM UM MAMìFERO". A invenção dirige-se a um método para tratar, prevenir, ou inibir uma infecção viral de hepatite C em um mamífero compreendendo contatar o mamífero com uma quantidade eficaz de um composto da fórmula (I) em que as substituições em R~ 1~-R~ 13~, m e Y são especificadas no relatório
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61214404P | 2004-09-23 | 2004-09-23 | |
| PCT/US2005/033803 WO2006034337A2 (en) | 2004-09-23 | 2005-09-21 | Carbazole and cyclopentaindole derivatives to treat infection with hepatitis c virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0515596A true BRPI0515596A (pt) | 2008-07-29 |
Family
ID=35907017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0515596-7A BRPI0515596A (pt) | 2004-09-23 | 2005-09-21 | composição farmacêutica usada para o tratamento e/ou prevenção de hcv, e, métodos de inibir rna polimerase ns5b de hepatite c de tratar ou prevenir infecção por hepatite c em um mamìfero |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7250441B2 (pt) |
| EP (1) | EP1793819A2 (pt) |
| JP (1) | JP2008514611A (pt) |
| CN (1) | CN101035528A (pt) |
| AU (1) | AU2005286727A1 (pt) |
| BR (1) | BRPI0515596A (pt) |
| CA (1) | CA2577413A1 (pt) |
| MX (1) | MX2007003371A (pt) |
| WO (1) | WO2006034337A2 (pt) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008520675A (ja) * | 2004-11-22 | 2008-06-19 | スミスクライン ビーチャム コーポレーション | Hcv阻害剤 |
| PE20070548A1 (es) | 2005-09-19 | 2007-07-12 | Emisphere Tech Inc | Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico |
| AU2007286754A1 (en) * | 2006-08-25 | 2008-02-28 | Viropharma Incorporated | Identification and characterization of HCV replicon variants with reduced susceptibility to HCV-796, and methods related thereto |
| KR20090106539A (ko) | 2006-12-22 | 2009-10-09 | 쉐링 코포레이션 | Hcv 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체 |
| JP5079818B2 (ja) | 2006-12-22 | 2012-11-21 | メルク・シャープ・アンド・ドーム・コーポレーション | Hcvおよび関連するウイルス疾患の治療または予防のための4,5−環インドール誘導体 |
| JP5055377B2 (ja) | 2006-12-22 | 2012-10-24 | シェーリング コーポレイション | [5,6−環]環形成インドール誘導体およびその使用方法 |
| MX2009011930A (es) | 2007-05-04 | 2009-11-18 | Vertex Pharma | Terapia de combinacion para el tratamiento de infeccion de virus de hepatitis c. |
| JP5179585B2 (ja) * | 2007-08-29 | 2013-04-10 | メルク・シャープ・アンド・ドーム・コーポレーション | 四環系インドール誘導体およびその使用法 |
| EP2195317B1 (en) | 2007-08-29 | 2012-01-18 | Schering Corporation | 2,3-substituted azaindole derivatives for treating viral infections |
| RU2010111550A (ru) | 2007-08-29 | 2011-10-10 | Шеринг Корпорейшн (US) | 2,3-замещенные индольные производные для лечения вирусных инфекций |
| WO2009032124A1 (en) | 2007-08-29 | 2009-03-12 | Schering Corporation | Substituted indole derivatives and methods of use thereof |
| KR101396696B1 (ko) * | 2007-10-10 | 2014-05-16 | 노파르티스 아게 | 스피로피롤리딘, 및 hcv 및 hiv 감염에 대한 그의 용도 |
| US8765757B2 (en) | 2007-11-16 | 2014-07-01 | Merck Sharp & Dohme Corp. | 3-heterocyclic substituted indole derivatives and methods of use thereof |
| CN102317285A (zh) | 2007-11-16 | 2012-01-11 | 先灵公司 | 3-氨基磺酰基取代的吲哚衍生物及其使用方法 |
| JP5580814B2 (ja) | 2008-06-13 | 2014-08-27 | メルク・シャープ・アンド・ドーム・コーポレーション | 3環式インドール誘導体およびその使用方法 |
| CN104311472B9 (zh) * | 2008-07-23 | 2020-03-17 | 艾尼纳制药公司 | 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物 |
| PL2342205T4 (pl) * | 2008-08-27 | 2016-12-30 | Podstawione tricykliczne pochodne kwasowe jako antagoniści receptora S1P1 użyteczni w leczeniu zaburzeń autoimmunologicznych i zapalnych | |
| ES2443948T3 (es) | 2008-12-19 | 2014-02-21 | Bristol-Myers Squibb Company | Compuestos de carbazol carboxamida útiles como inhibidores de quinasas |
| EP2528894A1 (en) | 2010-01-27 | 2012-12-05 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| CN105503882B (zh) | 2010-03-03 | 2019-07-05 | 艾尼纳制药公司 | 制备s1p1受体调节剂及其晶体形式的方法 |
| CN105566202B (zh) * | 2014-10-31 | 2018-06-22 | 华东师范大学 | 一种1,2,3,4-四氢环戊基吲哚衍生物及其合成方法 |
| CA3002540C (en) | 2015-01-06 | 2023-11-07 | Arena Pharmaceuticals, Inc. | Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor |
| JP6838744B2 (ja) | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩 |
| US20170107216A1 (en) | 2015-10-19 | 2017-04-20 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MD3377488T2 (ro) | 2015-11-19 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
| ES2916874T3 (es) | 2015-12-17 | 2022-07-06 | Incyte Corp | Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1 |
| CA3009474A1 (en) | 2015-12-22 | 2017-06-29 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| EP3464279B1 (en) | 2016-05-26 | 2021-11-24 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| SG11201811414TA (en) | 2016-06-20 | 2019-01-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| US20180057486A1 (en) | 2016-08-29 | 2018-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US10308644B2 (en) | 2016-12-22 | 2019-06-04 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
| KR20190113955A (ko) | 2017-02-16 | 2019-10-08 | 아레나 파마슈티칼스, 인크. | 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법 |
| SMT202300065T1 (it) | 2018-03-30 | 2023-05-12 | Incyte Corp | Composti eterociclici come immunomodulatori |
| CN112752756B (zh) | 2018-05-11 | 2024-06-25 | 因赛特公司 | 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物 |
| JP7397011B2 (ja) | 2018-06-06 | 2023-12-12 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1p1受容体に関連する状態を治療する方法 |
| EP3847158B1 (en) | 2018-09-06 | 2026-06-24 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
| TW202115059A (zh) | 2019-08-09 | 2021-04-16 | 美商英塞特公司 | Pd—1/pd—l1抑制劑之鹽 |
| JP7559059B2 (ja) | 2019-09-30 | 2024-10-01 | インサイト・コーポレイション | 免疫調節剤としてのピリド[3,2-d]ピリミジン化合物 |
| EP4058461A1 (en) | 2019-11-11 | 2022-09-21 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| IL302590A (en) | 2020-11-06 | 2023-07-01 | Incyte Corp | Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
| CN116854622A (zh) * | 2023-07-10 | 2023-10-10 | 青岛科技大学 | 一种多取代的2,4-二氢环戊二烯并[b]吲哚类化合物的合成方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0307077A1 (en) | 1987-07-21 | 1989-03-15 | Merck Frosst Canada Inc. | Tetrahydrocarbazoles for the improvement of cyclosporin therapy |
| US5830911A (en) * | 1996-08-14 | 1998-11-03 | American Home Products Corporation | Pyranoindole and tetrahydrocarbazole inhibitors of COX-2 |
| JP4126345B2 (ja) | 1997-03-06 | 2008-07-30 | 松森 昭 | ウイルス感染症の予防・治療剤 |
| CA2553814A1 (en) | 2004-01-29 | 2005-08-11 | Elixir Pharmaceuticals, Inc. | Treating a viral disorder |
-
2005
- 2005-09-21 WO PCT/US2005/033803 patent/WO2006034337A2/en not_active Ceased
- 2005-09-21 EP EP05815334A patent/EP1793819A2/en not_active Withdrawn
- 2005-09-21 US US11/230,729 patent/US7250441B2/en not_active Expired - Fee Related
- 2005-09-21 CN CNA2005800316732A patent/CN101035528A/zh active Pending
- 2005-09-21 CA CA002577413A patent/CA2577413A1/en not_active Abandoned
- 2005-09-21 AU AU2005286727A patent/AU2005286727A1/en not_active Abandoned
- 2005-09-21 BR BRPI0515596-7A patent/BRPI0515596A/pt not_active IP Right Cessation
- 2005-09-21 JP JP2007533604A patent/JP2008514611A/ja not_active Withdrawn
- 2005-09-21 MX MX2007003371A patent/MX2007003371A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US7250441B2 (en) | 2007-07-31 |
| WO2006034337A2 (en) | 2006-03-30 |
| US20060063821A1 (en) | 2006-03-23 |
| MX2007003371A (es) | 2007-05-07 |
| CA2577413A1 (en) | 2006-03-30 |
| JP2008514611A (ja) | 2008-05-08 |
| EP1793819A2 (en) | 2007-06-13 |
| WO2006034337A3 (en) | 2006-09-14 |
| AU2005286727A1 (en) | 2006-03-30 |
| CN101035528A (zh) | 2007-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0415883A (pt) | compostos e composições de nucleosìdeo para o tratamento de infecções virais | |
| SI1987038T1 (sl) | Hcv ns5b inhibitorji | |
| EA200900298A1 (ru) | Ингибиторы вируса гепатита с | |
| BR0305426A (pt) | Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos | |
| ATE469155T1 (de) | Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer | |
| DK1521754T3 (da) | Virale inhibitorer | |
| BR0315897A (pt) | agentes antiinfecciosos | |
| WO2004009020A3 (en) | Pyrrolopyrimidine thionucleoside analogs as antivirals | |
| BR0206614A (pt) | Composto, composição farmacêutica, método para inibir a polimerase viral de rna dependente de rna e/ou inibir a replicação viral de rna dependente de rna, método para tratar uma infecção viral de rna dependente de rna, e, uso de um composto | |
| MY164469A (en) | Hcv ns3 protease inhibitors | |
| BR0305259A (pt) | Inibidores de hcv ns5b polimerase | |
| NO20090453L (no) | Hepatitt C Virusinhibitorer | |
| DE60319820D1 (de) | Pyrazoloä1,5-aüpyrimidin-verbindungen als antivirale agentien | |
| NO20084637L (no) | Cyklopropyl-kondenserte indolobenzaepin HCV NS5B inhibitorer | |
| NO20071274L (no) | Inhibitorer av hepatitt C virus RNA-avhengig RNA polymerase, og sammensetninger og behandlinger ved anvendelse av samme. | |
| ATE512976T1 (de) | Hemmer des hepatitis-c-virus | |
| SG164376A1 (en) | Hcv ns3 protease inhibitors | |
| BR0306993A (pt) | Polìmero de polialquilenoglicol ativado; composição farmacêutica; método para tratar um paciente que tem uma infecção viral suscetìvel; e método para tratar um paciente suspeito de ter infecção por hepatite c | |
| ATE539744T1 (de) | Hemmer von serin-protease, insbesondere von hepatitis-c-virus-ns3-ns4a-protease, mit einem kondensierten ringsystem | |
| WO2006039488A3 (en) | Hcv ns3-ns4a protease inhibition | |
| PL376409A1 (en) | Composition for the treatment of infection by flaviviridae viruses | |
| ATE551337T1 (de) | Inhibitoren des hepatitis-c-virus | |
| MXPA05006196A (es) | Compuestos y metodos para el tratamiento o prevencion de infecciones por flavivirus. | |
| WO2006101538A3 (en) | Andrographolide derivatives to treat viral infections | |
| ATE498398T1 (de) | Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |